News

Net Loss of Bharat Parenterals reported to Rs 4.80 crore in the quarter ended March 2026 as against net loss of Rs 4.73 crore during the previous quarter ended March 2025. Sales declined 4.19% to Rs 99.62 crore in the quarter ended March 2026 as against Rs 103.98 crore during the previous quarter ended March 2025.For the full year,net loss reported to Rs 8.19 crore in the year ended March 2026 as against net loss of Rs 12.63 crore during the previous year ended March 2025. Sales rose 1.48% to Rs 345.43 crore in the year ended March 2026 as against Rs 340.38 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales99.62103.98 -4 345.43340.38 1 OPM %-0.532.14 -4.580.79 - PBDT0.260.22 18 12.831.37 836 PBT-8.37-8.30 -1 -21.42-33.95 37 NP-4.80-4.73 -1 -8.19-12.63 35 Powered by Capital Market - Live News

Bharat Parenterals announced that the Board of Directors of the Company at its meeting held on 18 May 2026, has recommended a Final Dividend of Rs.1 per share (i.e.10%), subject to the approval of the shareholders.

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 18 May 2026.

Net Loss of Bharat Parenterals reported to Rs 4.39 crore in the quarter ended December 2025 as against net loss of Rs 1.67 crore during the previous quarter ended December 2024. Sales declined 9.78% to Rs 65.19 crore in the quarter ended December 2025 as against Rs 72.26 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales65.1972.26 -10 OPM %2.675.04 - PBDT0.173.25 -95 PBT-8.28-5.50 -51 NP-4.39-1.67 -163 Powered by Capital Market - Live News

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 30 January 2026.Powered by Capital Market - Live News